Analysis of appropriateness and safety when discharging patients on triple-antithrombotic therapies.

This article evaluates the appropriateness and safety of triple-antithrombotic therapy—defined as the concurrent use of aspirin, a P2Y12 inhibitor, and an oral anticoagulant (OAC)—in patients discharged from Ochsner LSU Health Shreveport, based on the 2020 American College of Cardiology (ACC) consensus statement. In a retrospective review of 93 patients discharged on triple therapy between December 2020 and August 2022, only 33% received therapy meeting all criteria for correct indication, medication choice, dosing, and duration (no longer than 30 days). Prolonged duration beyond 30 days was the most common reason for inappropriateness, and safety outcomes included a 4.3% rate of major bleeding and 2 deaths within 30 days. The study highlights the complexity of managing triple therapy, the elevated bleeding risks associated with its prolonged use, and the need for improved adherence to guidelines and enhanced interdisciplinary communication to optimize patient outcomes.